Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II SABINA study of MEN1611 ± eribulin in PIK3CA/PTEN‑altered advanced metaplastic breast cancer
2022-001398-30Phase 2Active
- Sponsor
- Medica Scientia Innovation Research, S.L.
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of izorlisib in breast cancer (2 arms), sponsored by Medica Scientia Innovation Research, S.L. Primary endpoints: Objective response rate (ORR) – Cohort A, Time to response (TTR) – Cohort A and 3 more. Started Jan 2023; status: active.
02
Drugs
izorlisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2022-001398-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001398-30.